NSHBY yields 2.50% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, NSHBY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NSHBY + PFE for your $10,000?
Nisshinbo Holdings Inc., together with its subsidiaries, engages in the wireless and communications, micro devices, automobile brakes, precision instruments, chemicals, textiles, and real estate businesses worldwide. The company offers wireless communication equipment, including disaster-prevention systems and surveillance systems, mobile communication equipment for shipping and automobiles, power-supply and energy equipment, and ultrasonic sensors; and micro devices, which include CMOS operational amplifiers, SAW filters, and MEMS microphones. It also manufactures and supplies friction materials, such as disc pads and brake linings, and drum and disc brakes for use in compact cars, ordinary passenger cars, sports cars, large trucks, and buses, as well as for repairs and tests in garages and dealers; and molding products, precision parts, and system equipment, as well as electronic brake systems. In addition, the company manufactures and supplies rigid polyurethane foam/wastewater treatment carriers; carbodilite, a high-performance resin additive; bipolar plates for fuel cells; and amorphous carbon products, as well as shirts, uniforms, mobilons/elastomers, and oikos products. Further, it redevelops unused plant sites; leases office and commercial facilities; and sells housing lots. The company was incorporated in 1907 and is headquartered in Tokyo, Japan.
Full NSHBY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.